INTRODUCTION
Invasive lobular carcinoma (ILC) accounts for approximately 10-15% of newly diagnosed breast cancers (1, 2), affecting roughly 30,000 women annually in the United States (2). ILC is classically characterized by small, regular uniform neoplastic cells that invade the stroma in a single-file pattern with cells encircling normal breast tissue (1) . Inactivation of e-cadherin (CDH1) by a variety of molecular mechanisms is considered a defining characteristic of ILC.
When compared with the more common invasive breast cancers of no special type, also known as invasive ductal carcinomas (IDC), ILC is more likely to be estrogen receptorpositive and of lower nuclear grade (3) . ILC is often large at diagnosis and there have been numerous reports on the response to neoadjuvant chemotherapy. It was thought that patients with ILC are significantly less likely to have a pathological complete response than IDC patients, however a recent study concluded that ILC represents a heterogeneous group of tumours and the difference in response to neoadjuvant chemotherapy is largely explained by differences in molecular characteristics, particularly HR and HER2, and is independent of lobular histology (4) .ILC have been shown to respond well to endocrine therapy (2) and we recently described the clinical response to neoadjuvant letrozole in a series of 61 patients (3) . The lack of understanding of how lobular breast cancer responds to treatment is compounded by the paucity of research models (reviewed in 2), however a very recent study suggested that E2 and anti-estrogens differentially regulate ERα-mediated gene expression in ILC versus IDC cell lines and xenografts (5) .
Previous microarray studies of ILC tumours have focused on transcriptional differences between lobular and ductal histology before treatment (6-10).To our knowledge, there have been no previous studies on the molecular response to endocrine therapy in ILC patient samples. We and others have characterised the molecular response to endocrine therapy in breast tumours in previous studies (11-13), but have not previously considered the effects of histological subtype. Comparing pre-and post-treatment biopsies from the same patients, utilising the 'window of opportunity' afforded with neoadjuvant therapy is a powerful approach which can improve statistical power due to reducing patient-patient variation (14). However these studies are challenging to perform and are dependent on analysing sufficient numbers of suitably appropriate samples.
In this study we have performed the first gene expression profiling study of ILC treated with neoadjuvant letrozole and compare the molecular response to that of IDC. 
Materials and Methods

Patients
Tumour samples
Tumour biopsies were taken with a 14-guage needle before and approximately 2 weeks (range 10-19 days) and 3months (range 86-142 days) following commencement of continuous letrozole treatment as described previously ( Figure 1A ). Samples were snapfrozen in liquid nitrogen and frozen sections taken, stained with haematoxylin and eosin (H&E) and the cellularity and percentage presence of cancerous tissue within each specimen was assessed by a pathologist. Two week samples were available only for 10 of the 14 ILC patients.
Response assessment
Clinical response was determined using dynamic changes in tumour volumes assessed by repeated measurements taken over the 3 month treatment period. Primary assessment was based on ultrasound measurements performed by a single clinician (JMD) and these were verified by mammographic measurements ( Figure 1A) . Clinical response was defined as a reduction of greater than 70% in tumour volume by 3 months.
RNA Processing and microarray hybridisation
Biopsies were homogenised and RNA was extracted using the RNeasy Mini Kit with RNAsefree DNAse treatment (Qiagen). RNA quantity and quality was verified on a Bioanalyser 2100 with RNA 6000 Nano Kit (Agilent) and Nanodrop 2000c (Thermo Scientific). RNA was reverse transcribed and amplified using the WT-Ovation FFPE System Version 2 (NuGEN), purified using the Qiaquick PCR Purification Kit (Qiagen), biotinylated using the IL Encore Biotin Module (NuGEN), purified using minElute Reaction Cleanup Kit (Qiagen) and quantified once again using the Nanodrop 2000c (Thermo Scientific). Labelled cDNA was hybridised to Human HT-12v4 whole-genome expression beadarrays (Illumina) according to the standard protocol for NuGEN amplified samples. The Illumina data has been submitted to NCBI GEO and is available under GSE55374.Approximately half of the ILC and IDC samples were processed on Affymetrix GeneChips within a previous study [12] , these are publicly available from NCBI GEO under GSE20181 and identified in the supplementary file.
Data Analysis
The llumina and Affymetrix data were independently pre-processed and re-annotated to Ensembl gene identifiers, then combined and batch corrected as described previously(15).
Briefly, Illumina probe profiles were quantile normalised using the lumi package and mapped to Ensembl gene sequences using reMOAT (16) responded to letrozole. Patients were matched for clinicopathological features (Table 1) and response ( Figure 1B ) and the histopathological status was confirmed by a pathologist (representative images Figure 1C) . Consistent with previous studies (6-10), unsupervised hierarchical clustering of the pre-treatment samples using the 500 most variable genes across samples at pre-treatment was able to distinguish between IDC and ILC with 86% accuracy ( Figure 1D ). Gene set enrichment analysis confirmed consistency of the gene lists before and after treatment (p<0.0001). Therefore, differences in gene expression between ductal and lobular carcinomas are maintained during treatment, as illustrated using multidimensional scaling of the 206 pre-treatment genes with time plotted on the third dimension ( Figure 2C ).
Molecular differences between ILC and IDC are maintained on treatment
Highly similar molecular response to letrozole in ILC and IDC
Gene expression profiles of surgical samples after 3 months of letrozole treatment were compared with their representative patient-matched pre-treatment biopsy samples using a pair-wise Rank Products analysis (PFP=0.05) for ILC and IDC patients. Over half of the changed genes were significantly up or down regulated in both histological subtypes. Figure   3A clearly demonstrates that the molecular effects of treatment are virtually uniform (even after just 2 weeks), in the two subtypes, with the same genes up-and down-regulated. This result is somewhat at odds with a very recent study that found that E2 and anti-estrogens and IDC (MCF7, T47D and BT474) cell lines (5). However, we found that the 'ILC-specific' and 'IDC-specific' genes identified in this study were not significantly changed in the clinical samples after neoadjuvant letrozole using GSEA to compare the response between the histological subtypes (Supplemental Figure) . Furthermore, none of the differentially regulated genes highlighted in ILC cell lines and represented in our data (CA12, NEDD9, CXCL12, PDE4B and NR3C2) were significantly differently regulated between ILC and IDC tumours treated with letrozole (Supplemental Figure) . Perhaps not surprisingly and consistent with previous studies (12, 13), the genes that were most significantly changed in response to letrozole in both ILC and IDC tumours were characterised by down-regulation of proliferation and up-regulation of extracellular matrix remodelling and immune pathways ( Figure 3B ).
Discussion
Our study shows for the first time that the molecular response to endocrine therapy in ILCs is highly similar to the response in IDCs. This is somewhat surprising given that we and others (7-10), have demonstrated clear molecular differences between tumours prior to treatment. The present study demonstrates that these differences are maintained during treatment. Stratified medicine seeks to identify molecular differences between cancers that will allow targeted treatment with specific agents, yet although these histological subtypes of breast cancer are molecularly distinct, both respond in a highly uniform way to endocrine therapy. The consistent molecular changes in expression observed in response to letrozole in both ILC and IDC contrast with a recent study that found that E2 and anti-estrogens differentially regulate ERα-mediated gene expression in ILC and IDC cell lines (5). Whilst there are obvious possible explanations for this apparent discrepancy, including different responses to alternative endocrine agents and the degree to which a small number cell lines represent the molecular heterogeneity of primary breast tumours, we believe that our study demonstrates the value and need for performing molecular studies in patient samples undergoing treatment, rather than in cell lines. One of the possible reasons behind the similar molecular response to treatment observed in ILC and IDC in this study is that we selected only clearly responsive tumours from both histological subtypes.
Previous work from our group has suggested that there is greater molecular diversity in the gene changes seen between individual non-responding tumours when treated with aromatase inhibitors, whereas in responders the changes are relatively homogeneous (12). CAN-14-0620 Thus, the resistance mechanisms still may be different between the ILC and IDC despite the similarities found in responding tumours in the present study. We were unable to address this issue at this time, as there was only two non-responding lobular tumour with microarray data and therefore they were not included in this study. An extension of this study focused on the different resistance pathways in non-responding tumours of different pathological types may be possible in the future if additional samples can be collected.
However, we have already recorded that some non-responding tumours have molecular changes similar to responders; notably reductions in oestrogen-regulated and proliferation genes, without a clear clinical response (20).
Whilst the number of patients in this study is relatively modest, the ILC and IDC patient groups consist of cancers with a consistently high Allred ER score of 7 or 8, all were luminal A subtype, grade 2 or 3 and had similar responses to letrozole. Relatively high numbers of genes were significantly differentially expressed between the two subtypes, demonstrating clear distinctions between these cancers which was maintained at all time points. The study also supports the potential value of cross-platform integration to generate larger datasets with increased statistical power given that clinical samples are relatively scarce.
In conclusion, we have performed the first study of molecular changes in ILC in response to endocrine therapy. The genes which change on letrozole treatment are highly similar in ILC and IDC although clear molecular differences between the histological subtypes are evident between these two cancer types, and these differences are maintained on treatment. 
EGR1
